
    
      This is a randomized, double-blind, placebo-controlled study to assess the safety and
      tolerability of GRF6021, a plasma derived product, administered by intravenous (IV) infusion
      to subjects with Parkinson's disease (PD) and cognitive impairment. The study duration for
      the subjects will be approximately 7 months.
    
  